Format

Send to

Choose Destination
Br J Cancer. 2001 Dec 14;85(12):1838-41.

Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.

Author information

1
Division of Chemoprevention, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy.

Abstract

The effect on the IGF system of 60 mg and 600 mg daily of raloxifene administered for 2 weeks prior to surgery was investigated in 37 postmenopausal women with breast cancer. Raloxifene significantly decreased insulin-like growth factor (IGF-I) as compared to placebo (P < 0.05) with no dose-response relationship. No significant change was observed in IGFBP-3, while the IGF-I/IGFBP-3 molar ratio was decreased by treatment, with a statistically significant effect only for the higher dose. Given that high plasma levels of IGF-I have been suggested as a risk factor for breast cancer, these findings provide further support for the potential activity of raloxifene in breast cancer prevention.

PMID:
11747323
PMCID:
PMC2364027
DOI:
10.1054/bjoc.2001.2191
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center